QSAM Biosciences (QPWR) Stock Price, News & Analysis

Company Overview

QSAM Biosciences, Inc. (OTCMKTS:QPWR) is a clinical-stage biotechnology company focused on the development of adoptive T-cell immunotherapies for the treatment of solid tumors. The company’s core innovation is its proprietary QDive platform, a microengraving-based, high-throughput single-cell screening system designed to identify and enrich rare, high-avidity T-cell receptors (TCRs) capable of targeting tumor-associated antigens with precision.

The QDive platform enables parallel functional assays on millions of individual T cells to rapidly select lead candidates based on cytokine secretion, cytotoxic potential and antigen specificity. QSAM applies this approach to a pipeline of preclinical programs addressing antigens such as PSMA, mesothelin and MAGE-A4 in malignancies including prostate, ovarian and pancreatic cancers, with the goal of advancing optimized TCR-T cell products toward clinical evaluation.

Headquartered in Dallas, Texas, QSAM Biosciences collaborates with academic institutions and industry partners across North America and Europe to support its research and development efforts. The company’s leadership team brings together experts in immuno-oncology, cell therapy manufacturing and translational research, with a shared mission to translate innovative T-cell discovery technology into novel treatment options for patients with hard-to-treat solid tumors.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 437,200 shs
• Average Volume: 68,770 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Industrials
• Industry: Commercial Services & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:QPWR
• CIK: 1310527
• Web: q2earth.com
• Phone: (561) 693-1423
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A